|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5595756A
(en)
*
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
|
US6428788B1
(en)
|
1995-03-15 |
2002-08-06 |
Penn State University |
Compositions and methods for specifically targeting tumors
|
|
JP2002509158A
(ja)
|
1998-01-15 |
2002-03-26 |
センター・フォー・モレキュラー・メディシン・アンド・イムノロジー |
アーム付きリガンドの送達向上のための抗体と受容体ターゲティング部分
|
|
WO2001058479A1
(en)
|
2000-02-08 |
2001-08-16 |
The Penn State Research Foundation |
Immunotherapy using interleukin 13 receptor subunit alpha 2
|
|
US7541040B2
(en)
|
2001-12-04 |
2009-06-02 |
The United States Of America As Represented By The Department Of Health And Human Serivces |
Chimeric molecule for the treatment of th2-like cytokine mediated disorders
|
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
|
WO2003092717A1
(en)
|
2002-03-22 |
2003-11-13 |
The Penn State Research Foundation |
Cancer immunotherapy
|
|
ES2365210T3
(es)
|
2002-06-14 |
2011-09-26 |
Government Of The United States Of America, As Represented By The Secretary, Department Of Health |
Procedimientos de tratamiento y prevención de colitis en la que se implican la il-13 y los linfocitos t citolíticos naturales.
|
|
CN1878568A
(zh)
|
2003-11-05 |
2006-12-13 |
盘林京有限公司 |
Cdim结合抗体的增强的b细胞细胞毒性
|
|
EP1720908A2
(en)
|
2004-02-17 |
2006-11-15 |
Absalus, Inc. |
Super-humanized antibodies against respiratory syncytial virus
|
|
DK1791565T3
(en)
|
2004-09-23 |
2016-08-01 |
Genentech Inc |
Cysteingensplejsede antibodies and conjugates
|
|
AU2006210724A1
(en)
|
2005-02-03 |
2006-08-10 |
Antitope Limited |
Human antibodies and proteins
|
|
NZ612578A
(en)
|
2005-08-19 |
2014-11-28 |
Abbvie Inc |
Dual variable domain immunoglobin and uses thereof
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
EP2500355A3
(en)
|
2005-08-19 |
2012-10-24 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
SI1934174T1
(sl)
|
2005-10-07 |
2011-08-31 |
Exelixis Inc |
Inhibitorji MEK in postopki za njihovo uporabo
|
|
WO2007089871A2
(en)
|
2006-02-01 |
2007-08-09 |
The Johns Hopkins University |
Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
|
|
CL2008001334A1
(es)
|
2007-05-08 |
2008-09-22 |
Genentech Inc |
Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
|
|
PT2592148T
(pt)
|
2007-10-12 |
2018-11-12 |
Hoffmann La Roche |
Expressão proteica de múltiplos ácidos nucleicos
|
|
NZ584514A
(en)
|
2007-10-19 |
2012-07-27 |
Genentech Inc |
Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
|
|
US20160095939A1
(en)
|
2014-10-07 |
2016-04-07 |
Immunomedics, Inc. |
Neoadjuvant use of antibody-drug conjugates
|
|
ES3000111T3
(en)
|
2009-02-13 |
2025-02-27 |
Immunomedics Inc |
Intermediates for preparing conjugates with an intracellularly-cleavable linkage
|
|
CN101585880B
(zh)
|
2009-05-15 |
2011-10-26 |
中国人民解放军第四军医大学 |
一种抗人IL-13Rα2单克隆抗体的重链和轻链的可变区
|
|
UY33826A
(es)
|
2010-12-22 |
2012-07-31 |
Abbott Lab |
Proteínas de unión con dominios trivariables y sus usos
|
|
US20120201746A1
(en)
|
2010-12-22 |
2012-08-09 |
Abbott Laboratories |
Half immunoglobulin binding proteins and uses thereof
|
|
EP2828664B1
(en)
|
2012-03-19 |
2018-09-26 |
Stemline Therapeutics Inc. |
Methods for treating and monitoring the status of cancer
|
|
RS57694B1
(sr)
|
2012-10-12 |
2018-11-30 |
Adc Therapeutics Sa |
Pirolobenzodiazepin - anti-psma konjugati antitela
|
|
HRP20182129T1
(hr)
|
2012-10-12 |
2019-02-08 |
Adc Therapeutics Sa |
Konjugati protutijelo - pirolobenzodiazepin
|
|
WO2014057118A1
(en)
|
2012-10-12 |
2014-04-17 |
Adc Therapeutics Sarl |
Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
|
|
ES2680153T3
(es)
|
2012-10-12 |
2018-09-04 |
Adc Therapeutics Sa |
Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
|
|
EP2906296B1
(en)
|
2012-10-12 |
2018-03-21 |
ADC Therapeutics SA |
Pyrrolobenzodiazepine-antibody conjugates
|
|
EP2906297B1
(en)
|
2012-10-12 |
2017-12-06 |
ADC Therapeutics SA |
Pyrrolobenzodiazepine-antibody conjugates
|
|
SI2906252T1
(sl)
|
2012-10-12 |
2017-10-30 |
Adc Therapeutics Sa |
Pirolobenzodiazepin-anti-HER2 protitelesni konjugati
|
|
JP6392765B2
(ja)
|
2012-10-12 |
2018-09-19 |
エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ |
ピロロベンゾジアゼピン−抗体結合体
|
|
KR101763499B1
(ko)
|
2012-11-07 |
2017-07-31 |
화이자 인코포레이티드 |
항-il-13 수용체 알파 2 항체 및 항체-약물 접합체
|
|
WO2015012904A2
(en)
|
2012-12-13 |
2015-01-29 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
|
JP2016513098A
(ja)
|
2013-02-07 |
2016-05-12 |
イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． |
癌の標的治療用抗体と抱合した極めて強力なプロドラック形態の２−ピロリノドキソルビシン（ｐ２ｐｄｏｘ）
|
|
EP2970492B1
(en)
|
2013-03-15 |
2019-05-08 |
Wake Forest University Health Sciences |
Antibodies against human and canine il-13ra2
|
|
WO2014163684A1
(en)
|
2013-04-03 |
2014-10-09 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
TWI641620B
(zh)
|
2013-08-21 |
2018-11-21 |
再生元醫藥公司 |
抗－ｐｒｌｒ抗體及其用途
|
|
WO2015052534A1
(en)
|
2013-10-11 |
2015-04-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
|
WO2015052535A1
(en)
|
2013-10-11 |
2015-04-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
|
US20160256561A1
(en)
|
2013-10-11 |
2016-09-08 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
EP3054983B1
(en)
|
2013-10-11 |
2019-03-20 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
WO2015070210A1
(en)
|
2013-11-11 |
2015-05-14 |
Wake Forest University Health Sciences |
Epha3 and multi-valent targeting of tumors
|
|
JP6447933B2
(ja)
|
2014-02-21 |
2019-01-09 |
アイビーシー ファーマスーティカルズ，インコーポレイテッド |
Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療
|
|
GB201406767D0
(en)
|
2014-04-15 |
2014-05-28 |
Cancer Rec Tech Ltd |
Humanized anti-Tn-MUC1 antibodies anf their conjugates
|
|
BR112017005631A2
(pt)
|
2014-09-19 |
2018-06-26 |
City Of Hope |
células t com receptor de antígeno coestimulador quimérico direcionadas à il13ra2
|
|
CN107148285B
(zh)
|
2014-11-25 |
2022-01-04 |
Adc治疗股份有限公司 |
吡咯并苯并二氮杂䓬-抗体缀合物
|
|
CN107683289B
(zh)
|
2015-01-26 |
2021-08-06 |
芝加哥大学 |
IL13Rα2结合剂和其在癌症治疗中的用途
|
|
WO2016123143A1
(en)
|
2015-01-26 |
2016-08-04 |
The University Of Chicago |
CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2
|
|
GB201506389D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506409D0
(en)
|
2015-04-15 |
2015-05-27 |
Williams David G And Berkel Patricius H C Van And Howard Philip W |
Humanized anti-axl antibodies and their conjugates
|
|
GB201506388D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Cancer Res Technology Ltd And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506399D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506407D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506394D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506405D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506393D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201507827D0
(en)
|
2015-05-07 |
2015-06-17 |
Adc Therapeutics Sarl |
Diagnostic test
|
|
AU2016274989A1
(en)
|
2015-06-12 |
2017-11-02 |
Immunomedics, Inc. |
Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
|
|
JP6980980B2
(ja)
|
2015-06-25 |
2021-12-15 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
|
|
WO2017011342A1
(en)
|
2015-07-10 |
2017-01-19 |
Abbvie Inc. |
Igm-or-ige-modified binding proteins and uses thereof
|
|
GB201513607D0
(en)
|
2015-07-31 |
2015-09-16 |
Feingold Jay M |
Pyrrolobenzodiazepine-antibody conjugates
|
|
PE20181363A1
(es)
|
2015-09-23 |
2018-08-27 |
Genentech Inc |
Variantes optimizadas de anticuerpos anti-vegf
|
|
US10508143B1
(en)
|
2015-10-30 |
2019-12-17 |
Aleta Biotherapeutics Inc. |
Compositions and methods for treatment of cancer
|
|
CN108472365A
(zh)
|
2015-10-30 |
2018-08-31 |
艾丽塔生物治疗剂公司 |
用于肿瘤转导的组合物和方法
|
|
GB201602363D0
(en)
|
2016-02-10 |
2016-03-23 |
Adc Therapeutics Sa And Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
|
CN108601841A
(zh)
|
2016-02-10 |
2018-09-28 |
免疫医疗公司 |
Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
|
|
CN109195992A
(zh)
|
2016-04-29 |
2019-01-11 |
本康生物制药（深圳）有限公司 |
多特异性结合偶联物、相关的药物组合物及应用
|
|
WO2017210058A1
(en)
|
2016-06-01 |
2017-12-07 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with t-cell redirecting bispecific antibodies and checkpoint inhibitors
|
|
EP3548055A4
(en)
|
2016-12-02 |
2020-08-19 |
University of Southern California |
SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE
|
|
CA3050085A1
(en)
|
2017-01-20 |
2018-07-26 |
Juno Therapeutics Gmbh |
Cell surface conjugates and related cell compositions and methods
|
|
HUE056289T2
(hu)
|
2017-02-08 |
2022-02-28 |
Adc Therapeutics Sa |
Pirrolobenzodiazepin-antitest konjugátumok
|
|
RS61795B1
(sr)
|
2017-02-08 |
2021-06-30 |
Adc Therapeutics Sa |
Konjugati pirolobenzodiazepin antitela
|
|
CN108456250B
(zh)
*
|
2017-02-17 |
2025-11-28 |
恺兴生命科技(上海)有限公司 |
靶向il-13ra2的抗体及其应用
|
|
US20200306375A1
(en)
|
2017-02-22 |
2020-10-01 |
Aleta Biotherapeutics Inc. |
Compositions and methods for tumor transduction
|
|
CA3054885A1
(en)
*
|
2017-03-03 |
2018-09-07 |
Rinat Neuroscience Corp. |
Anti-gitr antibodies and methods of use thereof
|
|
AR111190A1
(es)
|
2017-03-22 |
2019-06-12 |
Genentech Inc |
Composiciones en hidrogel de prodrogas entrecruzadas de ácido hialurónico y métodos relacionados
|
|
MA49279A
(fr)
|
2017-03-22 |
2020-02-05 |
Hoffmann La Roche |
Compositions d'anticorps optimisées pour le traitement de troubles oculaires
|
|
US10799597B2
(en)
|
2017-04-03 |
2020-10-13 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
|
KR20210122319A
(ko)
|
2017-04-06 |
2021-10-08 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
비스-링키지를 사용한 세포독성 약물의 접합
|
|
MX2019012017A
(es)
|
2017-04-07 |
2020-02-12 |
Juno Therapeutics Inc |
Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
|
|
SG11201909160WA
(en)
|
2017-04-11 |
2019-10-30 |
Inhibrx Inc |
Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
|
|
EP3612839A1
(en)
|
2017-04-20 |
2020-02-26 |
ADC Therapeutics SA |
Combination therapy
|
|
WO2018193102A1
(en)
|
2017-04-20 |
2018-10-25 |
Adc Therapeutics Sa |
Combination therapy with an anti-axl antibody-drug conjugate
|
|
EP3612235A1
(en)
|
2017-04-20 |
2020-02-26 |
ADC Therapeutics SA |
Combination therapy with an anti-psma antibody-drug conjugate
|
|
EP3612236A1
(en)
|
2017-04-20 |
2020-02-26 |
ADC Therapeutics SA |
Combination therapy with an anti-cd25 antibody-drug conjugate
|
|
KR20200007905A
(ko)
|
2017-05-18 |
2020-01-22 |
리제너론 파마슈티칼스 인코포레이티드 |
사이클로덱스트린 단백질 약물 접합체
|
|
WO2018217227A1
(en)
|
2017-05-24 |
2018-11-29 |
Immunomedics, Inc. |
Novel anti-pd-1 checkpoint inhibitor antibodies that block binding of pd-l1 to pd-1
|
|
BR112019026498A2
(pt)
|
2017-06-14 |
2020-07-14 |
Adc Therapeutics Sa |
regimes de dosagem para a administração de um adc anti-cd25
|
|
CA3064804A1
(en)
|
2017-06-14 |
2018-12-20 |
Adc Therapeutics Sa |
Dosage regimes for the administration of an anti-cd19 adc
|
|
EP3480212B1
(en)
*
|
2017-11-03 |
2023-09-27 |
Consejo Superior De Investigaciones Científicas |
Il13ralpha2 peptide and its uses
|
|
MX2020004691A
(es)
|
2017-11-07 |
2020-08-20 |
Regeneron Pharma |
Enlazadores hidrofilicos para conjugados anticuerpo-farmaco.
|
|
JP7404252B2
(ja)
|
2017-11-08 |
2023-12-25 |
ヤフェイ シャンハイ バイオロジー メディスン サイエンス アンド テクノロジー カンパニー リミテッド |
生体分子のコンジュゲートおよびその使用
|
|
JP7542438B2
(ja)
|
2017-11-21 |
2024-08-30 |
ノバルティス アーゲー |
腫瘍関連抗原に対する三重特異性結合分子及びその使用
|
|
EP3621652A4
(en)
|
2017-12-31 |
2021-01-13 |
Hangzhou DAC Biotech Co, Ltd |
CONJUGATE OF ANALOGUE OF TUBULYSIN WITH BRANCHED LINKS
|
|
GB201802172D0
(en)
|
2018-02-09 |
2018-03-28 |
Adc Therapeutics S A |
Treatment of Car T-Cell Toxicity
|
|
GB201802312D0
(en)
|
2018-02-13 |
2018-03-28 |
Vib Vzw |
Melanoma disease stratification
|
|
EP3781176A4
(en)
|
2018-04-09 |
2022-05-25 |
The Trustees of the University of Pennsylvania |
METHODS AND COMPOSITIONS USING A VIRAL VECTOR FOR THE EXPRESSION OF A TRANSGENE AND AN EFFECTOR
|
|
KR20260046525A
(ko)
|
2018-04-11 |
2026-04-07 |
인히브릭스 바이오사이언스, 인크. |
제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
|
|
CA3099308A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by nk cells
|
|
CA3098103A1
(en)
|
2018-05-23 |
2019-11-28 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
EA202190189A1
(ru)
|
2018-07-05 |
2021-04-16 |
Ханчжоу Дэк Биотек Ко., Лтд |
Сшитое производное димера пирролобензодиазепина (pbd) и его конъюгаты
|
|
GB201811364D0
(en)
|
2018-07-11 |
2018-08-29 |
Adc Therapeutics Sa |
Combination therapy
|
|
EP3827019A1
(en)
|
2018-07-24 |
2021-06-02 |
Inhibrx, Inc. |
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
|
BR112021001338A2
(pt)
*
|
2018-07-26 |
2021-05-04 |
TCR2 Therapeutics Inc. |
composições e métodos para reprogramação de tcr usando proteínas de fusão específicas para o alvo
|
|
ES3037206T3
(en)
|
2018-08-31 |
2025-09-30 |
Adc Therapeutics Sa |
Combination therapy
|
|
IL282182B2
(en)
|
2018-10-12 |
2025-09-01 |
Hangzhou Dac Biotech Co Ltd |
Cytotoxic drug conjugates with a bis linkage
|
|
WO2020109251A1
(en)
|
2018-11-29 |
2020-06-04 |
Adc Therapeutics Sa |
Dosage regime
|
|
US20220062352A1
(en)
|
2018-12-03 |
2022-03-03 |
Demata Therapeutics, LLC |
Compositions for the treatment of conditions
|
|
WO2020052692A2
(en)
|
2018-12-04 |
2020-03-19 |
Novartis Ag |
Binding molecules against cd3 and uses thereof
|
|
WO2020127573A1
(en)
|
2018-12-19 |
2020-06-25 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine resistance
|
|
CA3128264A1
(en)
|
2019-01-31 |
2020-08-06 |
Hangzhou Dac Biotech Co., Ltd |
A conjugate of an amanita toxin with branched linkers
|
|
AU2020219736A1
(en)
|
2019-02-04 |
2021-09-30 |
Xenetic Biosciences, Inc. |
Methods of using glycopolysialylated therapeutic proteins
|
|
WO2020168106A1
(en)
|
2019-02-13 |
2020-08-20 |
Notable Labs, Inc. |
Combinations of agonists of protein kinase c with steroids or retinoic acids for the treatment of cancer
|
|
US20220362381A1
(en)
|
2019-02-21 |
2022-11-17 |
Bambu Vault Llc |
Remotely triggered therapy
|
|
US20220362295A1
(en)
|
2019-04-22 |
2022-11-17 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
AU2020267131A1
(en)
|
2019-05-02 |
2021-11-25 |
Revitope Limited |
TEAC and ATTAC immunooncology compositions and methods
|
|
US12037378B2
(en)
|
2019-05-21 |
2024-07-16 |
Novartis Ag |
Variant CD58 domains and uses thereof
|